NCT07219927 Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
| NCT ID | NCT07219927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-03-31 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
Eligibility Criteria
Inclusion Criteria: Participant has received a prescription for ONAPGO™ according to the standard of care. Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form. The HCP/Investigator determines the participant is an appropriate study participant. Participant is able and willing to provide informed consent (or informed assent form \[IAF\], as applicable) and signs the consent form on the Enrollment Day. Exclusion Criteria: Did not receive a prescription for ONAPGO™. Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study. Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron. Known hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).
Contact & Investigator
Mindy Grall, PhD ANP-BC
STUDY CHAIR
Supernus Pharmaceuticals, Inc.
Frequently Asked Questions
Who can join the NCT07219927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07219927 currently recruiting?
Yes, NCT07219927 is actively recruiting participants. Contact the research team at mgrall@supernus.com for enrollment information.
Where is the NCT07219927 trial being conducted?
This trial is being conducted at Aliso Viejo, United States, Irvine, United States, Palo Alto, United States, Boca Raton, United States and 1 additional location.
Who is sponsoring the NCT07219927 clinical trial?
NCT07219927 is sponsored by Supernus Pharmaceuticals, Inc.. The principal investigator is Mindy Grall, PhD ANP-BC at Supernus Pharmaceuticals, Inc.. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.